GlassScriptPhysician profile
Girish Patel
NPI 1588644991
$8,648.40
in general payments reported to CMS, 2019-2025
32 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $1,465 · 2021: $2,733 · 2022: $1,115 · 2023: $953 · 2024: $770 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,963.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,272.78 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Glaxosmithkline, LLC. | $1,097.97 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $464.22 | 2019-2022 | |
| Allergan, INC. | $410.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $381.11 | 2020-2024 | Farxiga, Airsupra |
| Gilead Sciences, INC. | $308.14 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $305.36 | 2022-2025 | Rexulti |
| Novo Nordisk INC | $269.09 | 2019-2025 | Ozempic |
| Medtronic, INC. | $237.96 | 2022-2023 | Corevalve Evolut R |
| Amgen INC. | $183.66 | 2020-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.84 | 2021-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.85 | 2025 | Caplyta |
| Amarin Pharma, INC. | $148.95 | 2019-2021 | |
| Madrigal Pharmaceuticals | $146.14 | 2025 | Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $125.00 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $119.17 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $100.71 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.73 | 2020-2021 | |
| Astellas Pharma US INC | $76.23 | 2020-2025 | Veozah |
| Abbott Laboratories | $75.45 | 2024 | Freestyle Libre |
| Lilly USA, LLC | $69.36 | 2020-2023 | Baqsimi, Jardiance, Lyumjev |
| Dexcom, INC. | $39.09 | 2021-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $36.09 | 2023-2025 | Eliquis, Camzyos |
| Viiv Healthcare Company | $30.89 | 2025 | Apretude |
| Kowa Pharmaceuticals America, INC. | $27.94 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $26.97 | 2021-2022 | |
| Hologic Sales and Service, LLC | $20.81 | 2025 | Aptima |
| Optinose US, INC. | $19.34 | 2021 | |
| Exact Sciences Corporation | $16.74 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $15.98 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.24 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Girish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.